GlassScriptPhysician profile
Kelli M Rose
NPI 1407028798
$4,064.18
in general payments reported to CMS, 2019-2025
26 companies · $883 in 2025
The $883 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $283 · 2021: $147 · 2022: $466 · 2023: $493 · 2024: $912 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.03 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $396.15 | 2019-2025 | |
| Glaxosmithkline, LLC. | $385.25 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $358.00 | 2020-2024 | Takhzyro, Cuvitru, Hyqvia |
| Octapharma USA, INC. | $335.04 | 2019-2025 | Cutaquig |
| Novartis Pharmaceuticals Corporation | $327.30 | 2019-2025 | |
| Csl Behring | $226.00 | 2019-2024 | Haegarda, Hizentra |
| Grifols USA, LLC | $167.83 | 2019-2025 | Prolastin-C Liquid, Gamunex-C, Xembify |
| Blueprint Medicines Corporation | $159.29 | 2023-2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $135.06 | 2019-2025 | Dupixent |
| Shire North American Group INC | $130.07 | 2019 | |
| Pharming Healthcare, INC. | $127.73 | 2022-2025 | Ruconest |
| Amgen INC. | $108.25 | 2023-2025 | Tezspire, Actimmune |
| Ars Pharmaceuticals Operations, INC. | $101.36 | 2025 | Neffy |
| Greer Laboratories, INC. | $90.67 | 2024-2025 | Palforzia, Oralair |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $88.14 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $87.98 | 2023-2025 | Orladeyo |
| Aimmune Therapeutics, INC. | $70.98 | 2020-2022 | |
| Pfizer INC. | $69.26 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.79 | 2019-2021 | |
| Kaleo, INC. | $48.38 | 2019-2021 | |
| Genentech USA, INC. | $33.34 | 2025 | Xolair |
| Incyte Corporation | $25.23 | 2023 | Opzelura |
| Lilly USA, LLC | $22.05 | 2024 | Ebglyss, Taltz |
| Leo Pharma INC. | $19.20 | 2022 | |
| Optinose US, INC. | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.